Drugs.com - Pharma Industry News

Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer

WEDNESDAY, Feb. 19, 2025 -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall...

Feb 19, 2025 - 18:52
 0
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
WEDNESDAY, Feb. 19, 2025 -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall...
Read More

Tags:

Previous Article

Depression Tied to Having More Physical Health Conditions

Next Article

Calls to Poison Centers on the Rise for Pediatric Exposures to Caffeine Energy P...

Related Posts

New Facial Plastic Surgery Survey Illustrates Impact of GLP-1 Receptor Agonists

New Facial Plastic Surgery Survey Illustrates Impact of...

Feb 9, 2025  0

2022 to 2023 Saw Decrease in Rate of Drug Overdose Deaths in United States

2022 to 2023 Saw Decrease in Rate of Drug Overdose Deat...

Feb 21, 2025  0

Four in 10 Patients Receiving Chemo Develop Chronic Painful Neuropathy

Four in 10 Patients Receiving Chemo Develop Chronic Pai...

Feb 9, 2025  0